Zoetis Announces U.S. FDA Approval of Librela™ (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs

Librela™ is the first and only injectable monoclonal antibody treatment for the control of canine OA pain approved in the United States



Zoetis continues to advance innovation with a new... | May 5, 2023

Related Keywords

Canada ,New Zealand ,Australia ,United Kingdom ,Brazil ,Japan ,Boston ,Massachusetts ,United States ,America ,Duncan Lascelles ,Laura Olsen ,Anaesth Analg ,Zoetis Inc ,Carolina State University ,Drug Administration ,Global Pain Council ,Animal Health Market Analysis ,Pettrak Us Pain Factored National ,European Medicines Agency ,Zoetis Services ,Professor Of Translational Research In Pain ,Unmet Need ,Senior Vice President ,Nerve Growth Factor ,Translational Research ,North Carolina State University ,Clinical Experience Reported ,South America ,Prescribing Information ,Looking Statements ,Annual Report ,Factors That May Affect Future ,Quarterly Reports ,Current Reports ,Canine Brief Pain Inventory ,Feline Pain Market ,Animal Health Market ,Small Anim Pract ,Demographics Sourcebook ,Factored National January ,Animals Workshop ,Librela Post Launch Tracker Wave ,Zoetis Stock Exchange ,News ,Information ,Press Release ,Us ,The ,First ,End ,Only ,Injectable ,Monoclonal ,Ntibody ,Treatment ,Or ,Control ,F ,Janine ,A ,Rain ,Approved ,N ,United ,Ontinues ,O ,Advance ,Innovation ,Ith Zts Us98978v1035 ,